Last reviewed · How we verify

B&A Therapeutics — Portfolio Competitive Intelligence Brief

B&A Therapeutics pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. China National Center for Cardiovascular Diseases · 1 shared drug class
  3. Ferrer Internacional S.A. · 1 shared drug class
  4. Heart Care Foundation · 1 shared drug class
  5. Instituto de Investigación Sanitaria Aragón · 1 shared drug class
  6. Jose J Zaragoza, MD MSc · 1 shared drug class
  7. Lakeland Regional Health Systems, Inc. · 1 shared drug class
  8. Aspirus Heart and Vascular Institute-Research and Education · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for B&A Therapeutics:

Cite this brief

Drug Landscape (2026). B&A Therapeutics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/b-a-therapeutics. Accessed 2026-05-16.

Related